Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




May
18
Today In Oncology
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC
Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study
Early Ovarian Cancer Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival
Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer
Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo